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Healthcare-associated infections caused bymultidrug-resistant
(MDR) Acinetobacter spp. have increased substantially worldwide,
including in Latin America.1 This is a major challenge, as several
isolates are only susceptible to polymyxins. Tigecycline provides a
new therapeutic option against this microorganism.2 Therefore,
surveillance of susceptibility to this drug is critical to detect
changes in its activity proﬁle. Regarding the medium used for
susceptibility testing, recent publications have suggested that the
susceptibility of Acinetobacter spp. isolates to tigecycline may vary
according to the commercial Mueller–Hinton agar (MHA) used in
the disk diffusion test. This could be because of the elevated
manganese concentration in MHA and may increase the reported
differences in minimum inhibitory concentration (MIC) values
obtained by different methodologies.3–6
We performed susceptibility testing on 60 MDR Acinetobacter
spp. isolates obtained from hospitalized patients at two teaching
hospitals inBuenosAires city, Argentina, over the course of two time
periods: 2002–2003 and 2006–2008. In vitro susceptibility was
assayed inparallel by thebrothmicrodilution, agardilution, anddisk
diffusion method with a 15mg tigecycline disk (Difco MHA, Difco
Laboratories, Detroit, MI, USA), as per the guidelines of the Clinical
and Laboratory Standards Institute (CLSI).7,8 Susceptibility was
inferred using the breakpoint suggested by the US Food and Drug
Administration (FDA) for Enterobacteriaceae (Tygacil package insert
(June 2005), Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA). A
comparative analysis between methods by scattergram correlation
and analysis of MICs and diameter zones around the disk was
performed. Staphylococcus aureus ATCC 29213, S. aureus ATCC
25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC
27853 and Enterococcus faecalis ATCC 29212 were used as controls.
A positive lineal correlation was found between methodologies.
Using the FDA Enterobacteriaceae susceptibility breakpoint for
tigecycline of <2mg/ml and >19mm, an acceptable minor errorTable 1
Interpretative criteria suggested by the US Food and Drug Administration (FDA) for
Enterobacteriaceae and calculated inter-method error rate for the disk diffusion
method
Methodologies ra MIC interpretive criteria, mg/ml
(correlate zone, mm)
Error rate
(%)
Susceptible Intermediate Resistant Major Minor
AD/BM 0.68 2 4 8 0.0 1.7b
AD/DD 0.62 2 (19) 4 (15–18) 8 (14) 0.0 15.4c
BM/DD 0.68 2 (19) 4 (15–18) 8 (14) 0.0 17,6c
MIC, minimum inhibitory concentration; AD, agar dilution; BM, broth microdilu-
tion; DD, disk diffusion.
a Scattergram correlation coefﬁcient (r).
b Acceptable level of inter-method discord or errors.
c Unacceptable level of inter-method discord or errors.
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unacceptable error by disk diffusionmethod (Table 1). These errors
were false-intermediateasMICresultswerebetween1and2mg/ml.
This suggests that disk diffusion is not the optimal method for
tigecycline susceptibility testing against Acinetobacter spp. There-
fore anothermethod such as agar dilution or brothmicrodilution is
recommended. However, this may be difﬁcult in resource-limited
settings where puriﬁed drugs and commercial microdilution
panels are not routinely available. In Argentina, disk diffusion is
the preferred method for testing tigecycline susceptibility against
MDR Acinetobacter spp. Recently, an Etest has been developed for
susceptibility testing of tigecycline; however there is discordance
in the results for Acinetobacter spp. according to some authors.9
This suggests that future studies are needed to evaluate its
usefulness for this microorganism.
These results propose, as also noted by Jones et al.,10 that an
adjustment in the disk diffusion breakpoint would reduce the
minor error rate to an acceptable level. However, this adjustment
should be donewith a standardized concentration ofmanganese in
the MHA. Further studies are needed to deﬁne the most adequate
methods for testing tigecycline susceptibility in Acinetobacter spp.
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